

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)



(10) International Publication Number
WO 2020/197991 A1

(51) International Patent Classification:

A61P 31/18 (2006.01) C07D 491/06 (2006.01)
C07D 471/04 (2006.01) A61K 31/4375 (2006.01)

(21) International Application Number:

PCT/US2020/023819

(22) International Filing Date:

20 March 2020 (20.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/822,703 22 March 2019 (22.03.2019) US
62/948,697 16 December 2019 (16.12.2019) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: CHU, Hang; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). GON-
ZALEZ BUENROSTRO, Ana Z.; c/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US). GUO, Hongyan; c/o Gilead Sciences, Inc., 333 Lake-
side Drive, Foster City, California 94404 (US). HAN,
Xiaochun; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, California 94404 (US). JIANG, Lan; c/
o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US). LI, Jiayao; c/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US). MITCHELL, Michael L.; c/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US). PYUN, Hyung-Jung; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
SCHROEDER, Scott D.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). SCH-
WARZWALDER, Gregg M.; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
SHAPIRO, Nathan D.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). SHI-
VAKUMAR, Devleena M.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). WU,
Qiaoyin; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, California 94404 (US). YANG, Hong; c/o

Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US). ZHANG, Jennifer R.; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US).

(74) Agent: BAJPAI, Reena et al.; Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: BRIDGED TRICYCLIC CARBAMOYL PYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE



I

(57) Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R¹, R², L, W¹, W², X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

WO 2020/197991 A1